S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market

Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

$128.60
+2.43 (+1.93%)
(As of 06/6/2023 ET)
Compare
Today's Range
$126.05
$130.32
50-Day Range
$120.20
$157.19
52-Week Range
$61.28
$159.89
Volume
768,387 shs
Average Volume
1.50 million shs
Market Capitalization
$11.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$168.76

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
31.2% Upside
$168.76 Price Target
Short Interest
Healthy
4.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
-0.08mentions of Sarepta Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($10.88) to $1.84 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

58th out of 981 stocks

Pharmaceutical Preparations Industry

21st out of 462 stocks


SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (SRPT)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy (SRPT)
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Sarepta Therapeutics (NASDAQ:SRPT) PT Lowered to $141.00
See More Headlines

SRPT Price History

SRPT Company Calendar

Last Earnings
5/02/2023
Today
6/06/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,162
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$168.76
High Stock Price Forecast
$218.00
Low Stock Price Forecast
$122.00
Forecasted Upside/Downside
+31.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
16 Analysts

Profitability

Net Income
$-703,490,000.00
Net Margins
-114.30%
Pretax Margin
-112.59%

Debt

Sales & Book Value

Annual Sales
$933.01 million
Book Value
$4.39 per share

Miscellaneous

Free Float
86,256,000
Market Cap
$11.98 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Douglas S. IngramDouglas S. Ingram
    President, Chief Executive Officer & Director
  • Ian M. Estepan
    Executive VP, Chief Financial & Accounting Officer
  • Louise Rodino-KlapacLouise Rodino-Klapac
    Chief Scientific Officer & Executive VP
  • Bilal Arif
    Chief Technical Operations Officer & Executive VP
  • Diane Berry
    EVP, Chief Global Policy & Advocacy Officer













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2023?

16 analysts have issued 1 year price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $122.00 to $218.00. On average, they expect the company's share price to reach $168.76 in the next year. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2023?

Sarepta Therapeutics' stock was trading at $129.58 at the beginning of the year. Since then, SRPT shares have decreased by 0.8% and is now trading at $128.60.
View the best growth stocks for 2023 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.46) by $0.49. The biotechnology company had revenue of $253.50 million for the quarter, compared to the consensus estimate of $241.47 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 128.64% and a negative net margin of 114.30%. The firm's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.20) EPS.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.67%), Wellington Management Group LLP (3.15%), Bank of New York Mellon Corp (2.06%), State Street Corp (1.90%), Geode Capital Management LLC (1.35%) and Pictet Asset Management SA (1.30%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $128.60.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $11.98 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($12.69) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 1,162 workers across the globe.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -